Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. User Boards ›
  4. NASDAQ DIP and RIP Message Board

BioPharm Updates: EGRX issued CRL; IPCI receives

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 23113
(Total Views: 579)
Posted On: 07/26/2017 9:44:43 PM
Avatar
Posted By: OldSaltDawg
BioPharm Updates:


EGRX issued CRL; IPCI receives thumbs down from Advisory Committee; Dynavax DVAX FDA briefing documents released
Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) announced that it has received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application for RYANODEX for the treatment of exertional heat stroke (EHS), in conjunction with external cooling methods. In its letter to Eagle, the FDA requested the company to conduct an additional clinical trial. Shares closed down 24% to $53.37.

Dynavax Technologies Corporation (NASDAQVAX) shares endured a volatile session, slipping over 20% in early trading before closing up 5% to $10.40 as investors digested key points noted in the FDA briefing documents released Wednesday for Friday’s Advisory Committee Meeting. The executive summary noted robust efficacy but with a lack of clarity in regard to safety:

In summary, Heplisav was shown to have a robust immune response in healthy adults 18- 70 years of age in Studies DV2-HBV-10 and-16. Heplisav met pre-specified noninferiority criteria to an active comparator vaccine, Engerix-B, in these two phase 3 clinical trials. Regarding safety, there appear to be imbalances in deaths and SAEs of MI in DV2-HBV-23, and imbalances in AESIs in DV2-HBV-16 and -23 (the studies that prospectively evaluated these events). Numbers and rates of events are low, and the lack of prospectively defined monitoring and evaluation of cardiac events limits the causal interpretation of these observations.

IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI) - An FDA Advisory Committee voted 22-1 against recommending approval of Rexista, a generic abuse and alcohol-deterrent controlled-release oral formulation of oxycodone hydrochloride for the relief of pain. The assigned PDUFA date is September, 25, 2017.

Gilead Sciences, Inc. (Nasdaq: GILD) shares are trading up 2.1% to $75.76 in the after-hours session following the release of 2Q financials. Total 12-month revenue waw $7.1 billion compared with consensus of $6.3b and $7.8 billion for the same period in 2016.

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) announced that it has commenced an underwritten offering of $60m of shares of its common stock. Shares are trading down 4% in the after-hours session to $7.55 after closing up 14% during normal hours.



Other Major price movers (stocks priced > $1.00, volume > 100k):

ADVANCERS:

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR): $1.88; +18%.

Immune Design Corp (NASDAQ:IMDZ): $11.65; +13%.

Apricus Biosciences Inc (NASDAQ:APRI): $1.26; +13%.

Axsome Therapeutics Inc (NASDAQ:AXSM): $6.15; +8%.

Moleculin Biotech Inc (NASDAQ:MBRX): $2.18; +8%.

DECLINERS:

Neuralstem, Inc. (NASDAQ:CUR): $2.47; -12%.

Pernix Therapeutics Holdings Inc (NASDAQTX): $3.15; -9%.

AnaptysBio Inc (NASDAQ:ANAB): $25.77; -8%.

Dicerna Pharmaceuticals Inc (NASDAQRNA): $3.98; -8%.

Soligenix, Inc. NASDAQ:SNGX): $2.40; -7%.



Pipeline updates below:

DRUG STAGE CATALYST
TICKER: EGRX
Ryanodex

Exertional heat stroke (EHS)
CRL CRL issued July 26, 2017. Additional trial required.

TICKER: ESPR

Bempedoic Acid - 1002-039

Hypercholesterolemia

PHASE 2 Phase 2 initiation announced July 26, 2017 - data due 1Q 2018.

TICKER: IPCI

Rexista

Pain relief

PDUFA PDUFA date September 25, 2017. Advisory Committee Meeting July 26, 2017 voted 22-1 against recommending approval.

TICKER: GSK

Inhaled PI3Kδ inhibitor

Chronic obstructive pulmonary disease (COPD)

PHASE 2B Phase 2b data due 1H 2019.

TICKER: GSK

Closed Triple - CAPTAIN

Asthma

PHASE 3 Phase 3 data due 2H 2018.

TICKER: GSK

GSK 165

Osteoarthritis

PHASE 2 Phase 2 data due 2H 2017.

TICKER: GSK

anti-SAP mAb

Amyloidosis

PHASE 2B Phase 2b data likely due 4Q 2017.

TICKER: GSK

Daprodustat - ASCEND-D

Anemia

PHASE 3 Phase 3 trial commenced 4Q 2016. Data due 2H 2020.

TICKER: GSK

Danirixin

Chronic obstructive pulmonary disease (COPD)

PHASE 2B Phase 2b data likely due 1Q 2019.

TICKER: GSK

Dolutegravir + lamivudine (GEMINI 2)

HIV

PHASE 3 Phase 3 trial commenced August 2016. Data likely due 1Q 2018.

TICKER: GSK

Dolutegravir + lamivudine (GEMINI 1)

HIV

PHASE 3 Phase 3 trial commenced August 2016. Data likely due 1Q 2018.

TICKER: GSK

Tapinarof

Atopic dermatitis, psoriasis

PHASE 3 Phase 3 data due 1H 2019.

TICKER: OPHT

Fovista

Wet age-related macular degeneration (Wet-AMD)

PHASE 3 Phase 3 data released December 12, 2016 - primary endpoint not met. Data from third trial due 3Q 2017 - company indicated that previous trial failures may be indicative of a low likelihood of success.
View in browser »


(1)
(0)




'Everything works out in the end,,,If it hasn't worked out,,it's not the end'


https://twitter.com/twitter/statuses/957208055766241280




Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us